inag c



OCT 0 3 2003

Nancy A. Noble et al.

Serial No.:

09/869,820

Filed:

July 5, 2001

Docket:

30434.4USWO

Title:

METHODS FOR TREATING CONDITIONS ASSOCIATED WITH THE ACCUMULATION

OF EXCESS EXTRACELLULAR MATRIX

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 29, 2003.

55 South Lake Avenue, Suite 710 Pasadena, California 91101 September 29, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

We are transmitting herewith the attached:

Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.

Supplemental Information Disclosure Statement (37 C.F.R. §1.97(c)(2))

Form 1449 (Information Disclosure Statement)

Exhibits 143 - 145

A check in the amount of \$180.00 to cover the filing fee.

Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

55 South Lake Avenue, Suite 710 Pasadena, California 91101 (626) 395-7801

Name: Sarah B. Adriano

Reg. No.: 34,470 Initials: SBA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Nancy A. Noble et al.

Serial No.:

09/869,820

Filed:

July 5, 2001

Docket:

30434.4USWO

Title:

METHODS FOR TREATING CONDITIONS ASSOCIATED WITH THE ACCUMULATION

OF EXCESS EXTRACELLULAR MATRIX

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 29, 2003.

By: Tracy Truick

55 South Lake Avenue, Suite 710 Pasadena, California 91101 September 29, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

We are transmitting herewith the attached:

- Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- Supplemental Information Disclosure Statement (37 C.F.R. §1.97(c)(2))
- Form 1449 (Information Disclosure Statement)
- **Exhibits** 143 145
- A check in the amount of \$180.00 to cover the filing fee.
- Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

55 South Lake Avenue, Suite 710 Pasadena, California 91101 (626) 395-7801 Name: Sarah B. Adriano

Reg. No.: 34,470 Initials: SBA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Nancy A. Noble et al.

Examiner:

Sean McGarry, Ph.D.

Serial No.:

09/869,820

Group Art Unit:

1635

Filed:

July 5, 2001

Docket No.:

30434.4USWO

Title:

METHODS FOR TREATING CONDITIONS ASSOCIATED WITH THE

ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 29, 2003.

By: Tracy Track

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R.\(\xi\).97(c)(2))

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This statement should be considered because it is submitted before the mailing date of a notice of allowance on the merits according to 37 C.F.R. §1.97(c)(2). In accordance with 37 C.F.R. §1.98(d), copies of Exhibits 143-145 as set forth in the Form 1449 are included herein.

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Australia Patent Application AU 1826/99 published July 15, 1999. (Exhibit 143)
- Moss, et al., "roles of vaccinia virus in the development of new vaccines," Vaccine, 1988,
 6:161-163. (Exhibit 144)
- Zelphati, Olivier et al., "Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes," Antisense and Research and Development, 1993, 3:323-38 (Exhibit 145)

Nancy A. Noble et al. Serial No. 09/862820

Filed: July 5, 2001 Page 2

OCT 0 3 2003

No representation and that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

A fee for the amount of \$180.00 is deemed necessary in connection with the filing of this Information Disclosure Statement on the merits of C.F.R.§1.97(c)(2). However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Registration No. 34,470

Roberta D. German

Registration No. 43,902

Patent Practitioners for Applicants

Mandel & Adriano

55 South Lake Avenue, Suite 710

Pasadena, California 91101

(626) 395-7801

Customer No. 26,941

FORM 1449*	Docket Number	Application Number			
	30434.4USWO	09/869,820			
O P E INFORMATION DISCLOSURE STATEMENT	Applicant Nancy A. Noble et al.				
IN AN APPLICATION					
(OCT 0 3 2003 H	Filing Date	Group Art Unit			
(Use several sheets if necessary)	July 5, 2001	1635			

II S PATENT DOCUMENTS												
WADE			U.S.	PATENT DOCUMENTS	S			***				
EXAMINER INITIAL			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
FOREIGN PATENT DOCUMENTS												
	DOCUMENT NO. AU 18267/99 (Exhibit 143)		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION					
							YES	NO				
			July 15, 1999	Australia								
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
•	Moss, et al., "Roles of vaccinia virus in the development of new vaccines," Vaccine, 1988, 6:161-163. (Exhibit 144											
		Zelphati, Olivier et al., "Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes," Antisense and Research and Development, 1993, 3:323-38 (Exhibit 145)										
_												
							<u> </u>					
							-					

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE